Drugs / S1 [arm: experimental] — 80 - 120 mg/day, PO, day 1-14
S1 [arm: experimental] — 80 - 120 mg/day, PO, day 1-14
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04465968 Background | Sep 2020 → Aug 2027 expected | lung superior sulcus carcinoma, non-small cell lung carcinoma | National Cancer Center Hospital East | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S1 [arm: experimental] — 80 - 120 mg/day, PO, day 1-14 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04465968 ↗ |
| Route | Oral | “80 - 120 mg/day, PO, day 1-14” NCT04465968 ↗ |